We are live on ! Find out more

Liquidia Corp

LQDA

Market cap $5.97B

66.74 USD

-1.11

1.64%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

66.81

+0.07

0.1%

1 day

-1.64%

5 days

-1.72%

1 month

-24.2%

3 months

-6.83%

6 months

73.08%

Year to date

112.55%

1 year

147.19%

5 years

2,362.73%

10 years

501.26%

About: Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Employees: 216

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 65.7%

Neutral 28.6%

Negative 5.7%

Zacks Investment Research

LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?

Liquidia's Yutrepia is gaining traction, but patent litigation, competition, rising costs and heavy product dependence cloud LQDA's outlook.

LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?

Zacks Investment Research

Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?

Liquidia's Yutrepia wins FDA Fast Track status for SSc-related Raynaud's, opening a potential new growth avenue for the lead drug.

Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?

FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis

Fast Track designation underscores the significant unmet need for patients with systemic sclerosis-associated Raynaud's phenomenon (SSc-RP), a debilitating manifestation affecting up to 90% of SSc patients No therapy is currently approved in the U.S. to treat SSc-RP and management options are limited and often inadequate for patients with more severe disease Liquidia plans to initiate RE-WARM, a Phase 2a dose-finding study of YUTREPIA in SSc-RP, in the fourth quarter of 2026 MORRISVILLE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to YUTREPIA® (treprostinil) inhalation powder for the treatment of Raynaud's phenomenon associated with systemic sclerosis (SSc-RP).

FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis

Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress

MORRISVILLE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it will present two posters at the European Respiratory Society (ERS) 2026 Congress taking place September 5-9, 2026, in Barcelona, Spain.

Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress

Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference

MORRISVILLE, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Michael Kaseta, Chief Operating Officer and Chief Financial Officer, and Jason Adair, Chief Business Officer, will provide an update on the company's business in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Boston on Tuesday, September 8, 2026 at 8:45 a.m.

Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference

Zacks Investment Research

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies could challenge its momentum.

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Zacks Investment Research

Is the Options Market Predicting a Spike in Liquidia Stock?

Investors need to pay close attention to LQDA stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Liquidia Stock?

Liquidia: A Linear Launch Priced For Exponential Growth

Liquidia Corporation is rated Sell due to YUTREPIA's decelerating growth and an overextended $6B+ valuation. YUTREPIA's percentage growth is compressing, prescriber acquisition has halved, and launch-era tailwinds are fading. Future growth will require difficult community penetration and overcoming structural headwinds from patient mortality and discontinuation.

Liquidia: A Linear Launch Priced For Exponential Growth

Zacks Investment Research

Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?

Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.

Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?

Zacks Investment Research

Will LQDA's Differentiated PAH Approach Drive Growth?

LQDA's Yutrepia is driving rapid growth, but intensifying PAH competition could test its ability to sustain momentum.

Will LQDA's Differentiated PAH Approach Drive Growth?

See News Rankings

Price charts implemented using Lightweight Charts™